MPWT
RAPP

MassMutual Private Wealth & Trust’s Rapport Therapeutics RAPP Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.79K Hold
163
– – ﹤0.01% 1568
2026
Q1 		$5.1K Buy
163
+2
+1% +$56 ﹤0.01% 1669
2025
Q4 		$4.88K Buy
+161
New +$4.46K ﹤0.01% 1681

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

MassMutual Private Wealth & Trust's RAPP Position: Q2 2026 in Review

MassMutual Private Wealth & Trust held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 163 shares worth $6.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1568.

MassMutual Private Wealth & Trust first reported a position in RAPP in Q4 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • MassMutual Private Wealth & Trust held 163 shares of Rapport Therapeutics worth $6.79K as of Q2 2026.
  • MassMutual Private Wealth & Trust left its Rapport Therapeutics share count unchanged in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #1568 holding.
  • MassMutual Private Wealth & Trust first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.